Skip to main content

Koselugo Disease Interactions

There are 2 disease interactions with Koselugo (selumetinib).

Moderate

Selumetinib (applies to Koselugo) cardiomyopathy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) >=10% below baseline, occurred in over 20% of pediatric patients who received selumetinib. The safety of this drug has not been established in patients with a history of impaired LVEF or an ejection fraction below the limit of normal. Caution is advised if using on these patients. Assess ejection fraction by echocardiogram prior to initiating treatment, and periodically during therapy.

References

  1. (2020) "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals
Moderate

Selumetinib (applies to Koselugo) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Selumetinib exposure is increased in patients with moderate or severe hepatic impairment. A recommended dosage has not been established for patients with severe hepatic impairment (Child-Pugh C), and a dose reduction is required in patients with moderate hepatic impairment (Child-Pugh B). Caution is advised when using in patients with these levels of hepatic impairment.

References

  1. (2020) "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals

Koselugo drug interactions

There are 224 drug interactions with Koselugo (selumetinib).

Koselugo alcohol/food interactions

There is 1 alcohol/food interaction with Koselugo (selumetinib).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer